Candriam Luxembourg S.C.A. trimmed its holdings in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 35.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 90,000 shares of the biotechnology company’s stock after selling 50,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in vTv Therapeutics were worth $541,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 1,976 shares during the period. Creative Planning bought a new position in shares of vTv Therapeutics during the 4th quarter worth about $114,000. JPMorgan Chase & Co. bought a new position in shares of vTv Therapeutics during the 3rd quarter worth about $481,000. Finally, Ameriprise Financial Inc. lifted its holdings in shares of vTv Therapeutics by 62.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after acquiring an additional 101,850 shares during the period. 11.19% of the stock is owned by institutional investors.
A number of equities analysts have recently commented on the stock. Northland Securities assumed coverage on shares of vTv Therapeutics in a report on Thursday, February 8th. They set an “outperform” rating and a $28.00 price objective for the company. Canaccord Genuity set a $15.00 price objective on shares of vTv Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Stifel Nicolaus reaffirmed a “buy” rating and set a $12.00 price objective on shares of vTv Therapeutics in a report on Friday, November 3rd. Finally, Citigroup reaffirmed an “add” rating on shares of vTv Therapeutics in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $16.42.
Shares of vTv Therapeutics Inc (NASDAQ VTVT) opened at $6.85 on Friday. The stock has a market cap of $218.86 and a PE ratio of -4.18. vTv Therapeutics Inc has a 1 year low of $3.57 and a 1 year high of $8.40.
In other news, Director Paul G. Savas bought 15,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was acquired at an average price of $4.56 per share, for a total transaction of $68,400.00. Following the transaction, the director now directly owns 81,781 shares of the company’s stock, valued at approximately $372,921.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ronald O. Perelman bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The shares were purchased at an average price of $4.03 per share, with a total value of $201,500.00. The disclosure for this purchase can be found here. Company insiders own 0.80% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Want to see what other hedge funds are holding VTVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for vTv Therapeutics Inc (NASDAQ:VTVT).
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.